1.Froehlich, TE, Lanphear, BP, Epstein, JN, Barbaresi, WJ, Katusic, SK, Kahn, RS. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med. 2007;161(9):857–864.
2.Faraone, SV, Sergeant, J, Gillberg, C, Biederman, J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2(2):104–113.
3.DuPaul, GJ, Power, TJ, Anastopoulos, AD, Reid, R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press. 1998.
4.Swanson, J, Lerner, M, March, J, Gresham, FM. Assessment and intervention for attention-deficit/hyperactivity disorder in the schools. Lessons from the MTA study. Pediatr Clin North Am. 1999;46(5):993–1009.
5.Swanson, JM, Kraemer, HC, Hinshaw, SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40(2):168–179.
6.Steele, M, Jensen, PS, Quinn, DMP. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006;28(11):1892–1908.
7.Frank, E, Prien, RF, Jarrett, RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):851–855.
8.Paykel, ES, Ramana, R, Cooper, Z, Hayhurst, H, Kerr, J, Barocka, A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25(6):1171–1180.
9.Miller, IW, Keitner, GI, Schatzberg, AF, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry. 1998;59(11):608–619.
10.Simon, GE, Revicki, D, Heiligenstein, J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry. 2000;22(3):153–162.
11.Tohen, M, Frank, E, Bowden, CL, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord. 2009;11(5):453–473.
12.Leucht, S, Davis, JM, Engel, RR, Kissling, W, Kane, JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl. 2009;119(suppl 438):7–14.
13.Biederman, J, Mick, E, Faraone, SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2000;157(5):816–818.
14.Stein, MA, Sarampote, CS, Waldman, ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112(5):e404.
15.Biederman, J, Krishnan, S, Zhang, Y, McGough, JJ, Findling, RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450–463.
16.Biederman, J, Boellner, SW, Childress, A, Lopez, FA, Krishnan, S, Zhang, Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62(9):970–976.
17.Wigal, SB, Kollins, SH, Childress, AC, Squires, L, for the 311 Study Group. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Mentl Health. 2009;3(1):17.
18.Findling, RL, Childress, AC, Krishnan, S, McGough, JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr. 2008;13(7):614–620.
19. Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Rev. Washington, DC: American Psychiatric Association; 2000:85–93.
20.Guy, W. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch; 1976;218–222.
21.Michelson, D, Allen, AJ, Busner, J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159(11):1896–1901.
22.Kelsey, DK, Sumner, CR, Casat, CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1):e1–e8.
23.Spencer, T, Heiligenstein, JH, Biederman, J, et al. Results from 2 proof-of-concept, placebo controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(12):1140–1147.
24.Spencer, T, Biederman, J, Wilens, T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58(8):775–782.
25.Kemner, JE, Starr, HL, Ciccone, PE, Hooper-Wood, CG, Crockett, RS. Outcomes of OROS® methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther. 2005;22(5):498–512.
26.Wigal, SB, McGough, JJ, McCracken, JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR®) and atomoxetine (Strattera®) in school aged children with attention deficit/hyperactivity disorder. J Atten Disord. 2005;9(1):275–289.
27.Greenhill, L, Wan, G, Cooper, K. Remission of ADHD symptoms with stimulant therapy. Poster presented at: the 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; Washington DC.
28.Steele, M, Weiss, M, Swanson, J, Wang, J, Prinzo, RS, Binder, CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 2006;13(1):e50–e62.
29.MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56(12):1073–1086.
30.Pelham, WE, Gnagy, EM, Burrows-Maclean, L, et al. Once-a-day Concerta® methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107(6):E105.
31.Efron, D, Jarman, F, Barker, M. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics. 1997;100(6):E6.
32.Ahmann, PA, Theye, FW, Berg, R, Linquist, AJ, Van Erem, AJ, Campbell, LR. Placebo-controlled evaluation of amphetamine mixture–dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects. Pediatrics. 2001;107(1):E10.
33.Weiss, M, Tannock, R, Kratochvil, C, et al. A randomized, placebo-controlled study of once daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44(7):647–655.
34.Goodman, D, Faraone, SV, Adler, LA, Dirks, B, Hamdani, M, Weisler, R. Interpreting ADHD Rating Scale scores: linking ADHD rating scale scores and CGI levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD. Primary Psychiatry. 2010;17(3):44–52.
35.Molina, BS, Hinshaw, SP, Swanson, JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):484–500.
36.Epstein, JN, Langberg, JM, Lichtenstein, PK, et al. Attention-deficit/hyperactivity disorder outcomes for children treated in community-based pediatric settings. Arch Pediatr Adolesc Med. 2010;164(2):160–165.
37.Biederman, J, Monuteaux, MC, Spencer, T, Wilens, TE, Faraone, SV. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics. 2009;124(1):71–78.